

Clinical Trial Protocol

Iranian Registry of Clinical Trials

02 Jun 2026

The Effects of Coenzyme Q10 Supplementation in Pediatrics with Chronic Kidney Disease stage 2 - 4 : A Randomized, Paralleled, Double blind, Controlled clinical trial

Protocol summary

Study aim

Proposing a new drug intervention to improve renal function.

Design

Randomized, paralleled, Double blind, controlled clinical trial with sample size of 60 patients

Settings and conduct

After entering the trial, patient will be randomly allocated to intervention and control groups by block randomization process. Physician and patients will be blind in this trial. Blood and urine samples will be taken at time 0 and three months after intervention and results are compared before and after the study and between both groups. This study will be conducted locally in Ali Asghar Children's Hospital.

Participants/Inclusion and exclusion criteria

Children diagnosed with Chronic Kidney Disease (CKD) stages 2 to 4
Entering criteria: 1.Age between 2 to 18 years old 2.Children diagnosed with CKD stages 2 to 4 based on estimated Glomerular Filtration Rate (eGFR)
Criteria for exclusion: 1.Liver disease 2.Autoimmune diseases 3.Kidney transplantation in last 6 months 4.Taking Corticosteroids and immunosuppressive medication

Intervention groups

After entering the trial, patient will be randomly allocated to intervention and control groups. Patients in the intervention group will take Q10, 3 mg per kg up to 100 mg daily adjuvant to their routine medication. Patients in control group will only receive their routine medication.

Main outcome variables

Blood Urea Nitrogen (BUN) level serum Creatinine level estimated Glomerular Filtration Rate (eGFR) Urine Protein level

General information

Reason for update

Acronym

co Q10

IRCT registration information

IRCT registration number: **IRCT20190722044303N1**

Registration date: **2019-12-25, 1398/10/04**

Registration timing: **registered_while_recruiting**

Last update: **2019-12-25, 1398/10/04**

Update count: **0**

Registration date

2019-12-25, 1398/10/04

Registrant information

Name

Pedram Shayesteh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2214 0806

Email address

peddy.sh@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-08-22, 1398/05/31

Expected recruitment end date

2020-02-19, 1398/11/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The Effects of Coenzyme Q10 Supplementation in Pediatrics with Chronic Kidney Disease stage 2 - 4 : A Randomized, Paralleled, Double blind, Controlled clinical trial

Public title

The Effects of Coenzyme Q10 Supplementation in Pediatrics with Chronic Kidney Disease : A Randomized, Paralleled, Double blind, Controlled clinical trial

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Age between 2 to 18 years old Diagnosed with Chronic Kidney Disease stage 2 - 4 according to estimated Glomerular Filtration Rate (eGFR) findings

Exclusion criteria:

Liver disease Chronic pulmonary disease Autoimmune disease Gastrointestinal dysfunction with the need for Parenteral nutrition Kidney transplantation in last 6 months Taking Antioxidants such as Vit E , L-Carnitine, or Omega 3 supplements in past 3 months Taking corticosteroids and/or immunosuppressive medication

Age

From **2 years** old to **18 years** old

Gender

Both

Phase

N/A

Groups that have been masked

- Participant
- Care provider

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients will be randomly divided into control and intervention groups using Blocked Randomization method. In this method, computer generated block sizes of 4 with equal probability will be used to enter eligible patients into one of the groups, intervention (Group B) and control (Group A). Initially one of the blocks will be randomly selected and the blocks will be repeatedly used to enter all eligible patients into one of the two groups. Patients in the intervention group (Group B) will be treated with the usual treatment regimen, plus Co Q10, 3 mg / kg and up to 100 mg daily for 3 months. In the control group, patients will receive only the usual treatment regimen.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, the physician and participants are blind. After the diagnosis of the disease, the physician will give the patients the envelopes on which A or B are written. The patient will deliver the envelope to the investigator, and after checking the inclusion and exclusion criteria of

the study, the patient will be assigned to either the control (A) or intervention (B) groups based on the envelopes. Only the investigator knows which group is intervention and which group is control.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Iran university of medical sciences

Street address

Iran University of Medical Sciences, Shahid Hemmat Highway

City

Tehran

Province

Tehran

Postal code

۱۴۳۹۶۱۴۵۳۵

Approval date

2019-07-16, 1398/04/25

Ethics committee reference number

IR.IUMS.REC.1398.407

Health conditions studied

1

Description of health condition studied

Chronic Kidney Disease

ICD-10 code

N18

ICD-10 code description

Chronic kidney disease (CKD)

Primary outcomes

1

Description

Blood Urea Nitrogen level

Timepoint

Before starting an intervention and three months after taking co enzyme Q10 supplement

Method of measurement

Blood test, Photometric kit

2

Description

Creatinine level

Timepoint

Before starting an intervention and three months after taking co enzyme Q10 supplement

Method of measurement

Blood test, photometric kit

3

Description

eGFR

Timepoint

Before starting an intervention and three months after taking co enzyme Q10 supplement

Method of measurement

Calculation based on blood Creatinine and patient's height

4

Description

Proteinuria

Timepoint

Before starting an intervention and three months after taking co enzyme Q10 supplement

Method of measurement

Urine test, Dipstick

Secondary outcomes

1

Description

C-Reactive Protein (CRP) level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, Agglutination method

2

Description

Erythrocyte Sedimentation Rate (ESR) level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, Photometric kit

3

Description

Fasting blood Glucose level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, Photometric test

4

Description

Alanine Aminotransferase (ALT) level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, photometric kit

5

Description

Aspartate Aminotransferase (AST) level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, photometric kit

6

Description

Blood Triglyceride level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, photometric kit

7

Description

Low Density Lipoprotein (LDL) level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, photometric kit

8

Description

High Density Lipoprotein (HDL) level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, photometric kit

9

Description

Total Cholesterol level

Timepoint

Before starting the intervention and 3 months after taking co enzyme Q10 supplement

Method of measurement

Blood test, photometric kit

10

Description

Urine protein level

Timepoint

Before starting the intervention and 3 months after

taking co enzyme Q10 supplement

Method of measurement

Urine test, Dipstick method

Intervention groups**1****Description**

Intervention group: After entering the trial, patients will be prescribed to take co enzyme Q10 supplement from Nutri Century Corporation 3 mg per kg up to 100 mg daily adjuvant to their routine medication.

Category

Treatment - Drugs

2**Description**

Control group: After entering the trial, patients will only receive their routine medications without Q10. Blood and urine tests will be taken at time 0 and three months after taking Q10.

Category

N/A

Recruitment centers**1****Recruitment center****Name of recruitment center**

Ali asghar children's hospital

Full name of responsible person

Pedram Shayesteh

Street address

Zafar street , Modarres Highway

City

Tehran

Province

Tehran

Postal code

1919816766

Phone

+98 21 2222 2041

Email

aach@iums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Abbas Motevalian

Street address

Shahid Hemmat Highway, Tehran, 1449614535, IRAN

City

Tehran

Province

Tehran

Postal code

۱۴۴۹۶۱۴۵۳۵

Phone

+98 21 86701

Email

admins@iums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Iran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Pedram Shayesteh

Position

Student

Latest degree

Bachelor

Other areas of specialty/work

Medical Pharmacy

Street address

No.D3, Sarv 7 Building, Koohestan towers, Koohestan street, Ketab square, Saadat abad, Tehran

City

Tehran

Province

Tehran

Postal code

198118395

Phone

+98 21 2214 0806

Fax**Email**

peddy.sh@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Parastoo Mirzabeygi

Position

Associate Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Ali Asghar children Hospital, Zafar street, Modarres Highway

City

Tehran

Province

Tehran

Postal code

1919816766

Phone

+98 21 2222 2041

Email

mirzabeygi.p@iums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Pedram Shayesteh

Position

Student

Latest degree

Bachelor

Other areas of specialty/work

Medical Pharmacy

Street address

No.D3, Sarv 7 Building, Koohestan towers, Koohestan street, Ketab squire, Saadat abad, Tehran

City

Tehran

Province

Tehran

Postal code

1981118395

Phone

+98 21 2214 0806

Fax**Email**

peddy.sh@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

No more information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available